Serum amyloid A levels in patients with liver diseases

Table 1 Serum levels of serum amyloid A in different groups of subjects

Subjects (n)	mean ± SD, (mg/L)	Median (minimum-maximum), (mg/L)	Z1 (compared with healthy controls/active CHB)	P1 (compared with healthy controls/ active CHB)
Healthy controls (117)	2.902 ± 1.801	2.250 (0.797-9.040)	-	-
Inactive CHB (146)	2.936 ± 3.092	2.350 (0.800-29.90)	-1.129/-7.281	0.259/< 0.001
Active CHB (59)	6.621 ± 6.776	4.000 (1.700-39.90)	-5.980	< 0.001
NASH (21)	6.624 ± 4.891	5.500 (2.800-23.00)	-4.867	< 0.001
Drug-induced liver injury (14)	8.036 ± 5.685	6.800 (3.400-26.20)	-4.992	< 0.001
Autoimmune liver disease (22)	19.73 ± 24.81	13.70 (3.300-108.0)	-6.870	< 0.001
Pyogenic liver abscess (16)	398.4 ± 246.8	413.5 (62.20-871.0)	-6.474	< 0.001

¹Mann-Whitney U test was used to compare the serum amyloid A levels between various liver disease groups and the healthy control group, and Bonferroni test was applied for post hoc comparisons to control the probability of type 1 error (alpha = 0.05/6 = 0.008). CHB: Chronic hepatitis B; NASH: Nonalcoholic steatohepatitis.